Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine + nifedipine is a combination of two dihydropyridine calcium channel blockers. Both drugs act by inhibiting L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Amlodipine is a third-generation dihydropyridine with a long duration of action, while nifedipine is an earlier generation agent with rapid onset but shorter duration. Both are primarily indicated for the treatment of hypertension and angina pectoris. Their combined use would theoretically provide additive antihypertensive effects due to their similar mechanisms, though this specific combination is not standard clinical practice and may increase the risk of adverse effects such as hypotension or peripheral edema[1][2][9]. Both agents have also demonstrated pulmonary vasodilatory properties and potential benefit in conditions like pulmonary hypertension[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine + nifedipine.